NAGE

⚡ 1-Minute Take

Data sources: market data, fundamentals, news providers. Data may be delayed.

Key Statistics

MoonshotScore Breakdown: 53.0/100

📰 Latest News

Niagen Bioscience Inc pioneers healthy aging through nicotinamide adenine dinucleotide (NAD+) research, boasting a strong 16.4% profit margin and positioning itself as a key player in the burgeoning longevity market, offering investors a unique opportunity in the biotechnology sector.

About NAGE

Niagen Bioscience Inc is a biotechnology company focused on healthy aging through research on nicotinamide adenine dinucleotide. The company currently has a market capitalization of $0.41 billion and a profit margin of 16.4%.

Niagen Bioscience Inc Company Overview

Niagen Bioscience Inc, headquartered in Los Angeles, is a biotechnology company dedicated to advancing the science of healthy aging. The company's core focus revolves around the research and development of interventions targeting nicotinamide adenine dinucleotide (NAD+), a critical coenzyme present in all living cells. NAD+ plays a vital role in numerous cellular processes, including energy production, DNA repair, and cellular signaling. As individuals age, NAD+ levels naturally decline, contributing to age-related decline and disease. Niagen Bioscience aims to combat this decline through innovative research and potential therapeutic applications. The company's research efforts are geared towards understanding the mechanisms by which NAD+ influences aging and developing strategies to boost NAD+ levels safely and effectively. With a team of dedicated scientists and researchers, Niagen Bioscience is at the forefront of the healthy aging movement, seeking to translate scientific discoveries into tangible benefits for individuals seeking to live longer, healthier lives. The company's current market position reflects its commitment to innovation and its potential to disrupt the aging process. Niagen Bioscience operates primarily in the research and development phase, focusing on preclinical and clinical studies to validate the efficacy and safety of its NAD+-boosting interventions. The company's geographic reach is primarily focused on the United States, with potential for future expansion into international markets. Niagen Bioscience faces competition from other companies in the biotechnology and nutraceutical industries that are also exploring interventions to promote healthy aging. However, the company's focus on NAD+ research and its scientific expertise provide a competitive advantage in this rapidly evolving field.

Investment Thesis

Investing in Niagen Bioscience Inc presents a compelling opportunity due to its focus on the rapidly growing healthy aging market. With a market capitalization of $0.41 billion and a solid profit margin of 16.4%, the company demonstrates financial stability and growth potential. The increasing awareness of NAD+'s role in aging, coupled with Niagen Bioscience's pioneering research, positions it for significant growth. Key value drivers include successful clinical trials demonstrating the efficacy of NAD+-boosting interventions, strategic partnerships with pharmaceutical companies, and expansion into new markets. Upcoming catalysts include the publication of clinical trial results in Q3 2026 and potential FDA approval for novel NAD+ boosting compounds by 2027. This makes NAGE an attractive investment for those seeking exposure to the longevity market.

Key Financial Highlights

• Market Cap of $0.41B indicates a strong market valuation.
• P/E ratio of 23.31 suggests the company is trading at a reasonable valuation compared to its earnings.
• Profit Margin of 16.4% demonstrates efficient operations and profitability.
• Gross Margin of 63.9% highlights the company's ability to control costs and generate revenue.
• Beta of 2.09 indicates higher volatility compared to the market, potentially offering higher returns but also higher risk.

Industry Context

Niagen Bioscience operates within the biotechnology industry, specifically targeting the healthy aging market. This market is experiencing significant growth, driven by an aging global population and increasing awareness of preventative healthcare. The competitive landscape includes companies like AKBA Therapeutics, CRVS Corporation, KALV Corporation, KROS Corporation, and OLMA Corporation, which are also developing interventions for age-related diseases. The global market for anti-aging products and services is projected to reach $421.4 billion by 2030, growing at a CAGR of 7.5% from 2023 to 2030. Niagen Bioscience is positioned to capitalize on this trend through its focus on NAD+ research and development.

Quarterly Financial Summary

Source: Company filings. Data may be delayed.

Growth Opportunities

• Expansion into International Markets: Niagen Bioscience has the opportunity to expand its geographic reach beyond the United States into international markets, particularly in Asia and Europe, where there is a growing demand for healthy aging products and services. The global market for dietary supplements is projected to reach $278 billion by 2028, providing a significant opportunity for Niagen Bioscience to increase its revenue and market share. Timeline: 2027-2028.
• Development of Novel NAD+ Boosting Compounds: Niagen Bioscience can invest in research and development to create new and improved NAD+ boosting compounds with enhanced efficacy and bioavailability. This could involve exploring novel delivery methods, such as liposomes or nanoparticles, to improve the absorption and utilization of NAD+ in the body. The market for drug delivery technologies is projected to reach $24 billion by 2027. Timeline: Ongoing.
• Strategic Partnerships with Pharmaceutical Companies: Niagen Bioscience can form strategic partnerships with pharmaceutical companies to co-develop and commercialize NAD+ boosting therapies for age-related diseases. This could involve licensing its intellectual property or collaborating on clinical trials to validate the efficacy of its products. The global pharmaceutical market is projected to reach $1.57 trillion by 2028. Timeline: 2026-2027.
• Direct-to-Consumer Marketing: Niagen Bioscience can implement a direct-to-consumer marketing strategy to increase awareness and sales of its NAD+ boosting supplements. This could involve utilizing online advertising, social media marketing, and influencer collaborations to reach a wider audience. The global market for online advertising is projected to reach $646 billion by 2024. Timeline: Ongoing.
• Clinical Trials for Specific Age-Related Diseases: Niagen Bioscience can conduct clinical trials to evaluate the efficacy of its NAD+ boosting interventions in treating specific age-related diseases, such as Alzheimer's disease, Parkinson's disease, and cardiovascular disease. Positive clinical trial results could lead to FDA approval and increased adoption of its products. The global market for Alzheimer's disease therapeutics is projected to reach $13.7 billion by 2028. Timeline: Ongoing.

Competitive Advantages

• Proprietary NAD+ boosting compounds and formulations.
• Strong intellectual property portfolio with patents protecting its technologies.
• Scientific expertise and research capabilities in the field of NAD+ metabolism.
• Established brand reputation and credibility in the healthy aging market.

Strengths

• Pioneering research in NAD+ and healthy aging.
• Strong intellectual property portfolio.
• Experienced management team with scientific expertise.
• High gross margin of 63.9%.

Weaknesses

• Reliance on a single area of research (NAD+).
• Limited product portfolio.
• High beta of 2.09 indicates significant volatility.
• Small number of employees (104).

Opportunities

• Expansion into new markets and product lines.
• Strategic partnerships with pharmaceutical companies.
• Positive clinical trial results leading to FDA approval.
• Growing demand for healthy aging products and services.

Threats

• Competition from other biotechnology and nutraceutical companies.
• Regulatory hurdles and potential changes in regulations.
• Unfavorable clinical trial results.
• Economic downturn affecting consumer spending on discretionary products.

What NAGE Does

• Researches nicotinamide adenine dinucleotide (NAD+) and its role in healthy aging.
• Develops interventions to boost NAD+ levels in the body.
• Conducts preclinical and clinical studies to evaluate the efficacy and safety of its products.
• Seeks to translate scientific discoveries into tangible benefits for individuals.
• Focuses on understanding the mechanisms by which NAD+ influences aging.
• Aims to combat age-related decline and disease through innovative research.
• Explores novel delivery methods to improve the absorption and utilization of NAD+.

Business Model

• Develops and patents NAD+ boosting compounds.
• Conducts research and clinical trials to validate the efficacy of its products.
• Commercializes its products through direct-to-consumer sales and partnerships.
• Generates revenue through the sale of NAD+ boosting supplements and potential licensing agreements.

Key Customers

• Individuals seeking to improve their overall health and well-being.
• Adults experiencing age-related decline and seeking to maintain their vitality.
• Healthcare professionals interested in incorporating NAD+ boosting therapies into their practice.
• Pharmaceutical companies seeking to develop new treatments for age-related diseases.

Competitors

• Akebia Therapeutics Inc (AKBA): Focuses on kidney disease treatments.
• Corvus Pharmaceuticals Inc (CRVS): Develops cancer immunotherapies.
• KalVista Pharmaceuticals Inc (KALV): Specializes in hereditary angioedema treatments.
• Keros Therapeutics Inc (KROS): Develops treatments for hematological and pulmonary disorders.
• Olma Pharmaceuticals Inc (OLMA): Focuses on oncology therapies.

Catalysts

• Upcoming: Publication of clinical trial results in Q3 2026 demonstrating the efficacy of NAD+ boosting interventions.
• Upcoming: Potential FDA approval for novel NAD+ boosting compounds by 2027.
• Ongoing: Strategic partnerships with pharmaceutical companies to co-develop and commercialize NAD+ boosting therapies.
• Ongoing: Expansion into new markets and product lines to increase revenue and market share.

Risks

• Potential: Unfavorable clinical trial results that could negatively impact the company's valuation.
• Potential: Regulatory hurdles and potential changes in regulations that could delay or prevent the approval of its products.
• Ongoing: Competition from other biotechnology and nutraceutical companies that are also developing interventions for age-related diseases.
• Ongoing: Economic downturn affecting consumer spending on discretionary products, such as NAD+ boosting supplements.

FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Related Stocks in Biotechnology

Browse More

Next Steps